| Michael Leigh Wells, MD | |
|
200 1st St Sw, Rochester, MN 55905-0001 | |
| (507) 284-2511 | |
| Not Available |
| Full Name | Michael Leigh Wells |
|---|---|
| Gender | Male |
| Speciality | Diagnostic Radiology |
| Experience | 15 Years |
| Location | 200 1st St Sw, Rochester, Minnesota |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1013147263 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 2085R0202X | Radiology - Diagnostic Radiology | 105034 (Minnesota) | Secondary |
| 2085R0202X | Radiology - Diagnostic Radiology | 53513 (Minnesota) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Mayo Clinic Hospital Rochester | Rochester, MN | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Mayo Clinic | 6507778255 | 4232 |
News Archive
The brain continues to put up a fight even as neurodegenerative diseases like dementia damage certain areas and functions. In fact, recent findings in a Baycrest-University of Arizona study suggest that one method the brain uses to counter these diseases is the reassigning of tasks to different regions.
As Pisgah Laboratories, Inc. continues development of its lead abuse deterrent opioid product, it will soon begin scale-up of its patent-pending form of hydrocodone. Pisgah has developed a specialized salt form of hydrocodone which imparts abuse deterrent properties to a dosage product. Pisgah will manufacture its hydrocodone salt for clinical trials in their FDA / DEA registered facility.
In the US, child-resistant packaging for most medications has contributed to the prevention of thousands of pediatric deaths. Nevertheless, over 500,000 calls are made to poison control centers each year after accidental ingestion of medications by young children, and the number of emergency department visits for unsupervised medication ingestions is rising.
Oxford Gene Technology, provider of innovative genetics research and biomarker solutions to advance molecular medicine, has released the results from a recent survey of researchers using next generation sequencing.
› Verified 7 days ago
| Entity Name | Mayo Clinic |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1922074434 PECOS PAC ID: 6507778255 Enrollment ID: O20031103000285 |
News Archive
The brain continues to put up a fight even as neurodegenerative diseases like dementia damage certain areas and functions. In fact, recent findings in a Baycrest-University of Arizona study suggest that one method the brain uses to counter these diseases is the reassigning of tasks to different regions.
As Pisgah Laboratories, Inc. continues development of its lead abuse deterrent opioid product, it will soon begin scale-up of its patent-pending form of hydrocodone. Pisgah has developed a specialized salt form of hydrocodone which imparts abuse deterrent properties to a dosage product. Pisgah will manufacture its hydrocodone salt for clinical trials in their FDA / DEA registered facility.
In the US, child-resistant packaging for most medications has contributed to the prevention of thousands of pediatric deaths. Nevertheless, over 500,000 calls are made to poison control centers each year after accidental ingestion of medications by young children, and the number of emergency department visits for unsupervised medication ingestions is rising.
Oxford Gene Technology, provider of innovative genetics research and biomarker solutions to advance molecular medicine, has released the results from a recent survey of researchers using next generation sequencing.
› Verified 7 days ago
| Entity Name | Mayo Clinic Health System-lake City |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1164463659 PECOS PAC ID: 1951213487 Enrollment ID: O20031104000095 |
News Archive
The brain continues to put up a fight even as neurodegenerative diseases like dementia damage certain areas and functions. In fact, recent findings in a Baycrest-University of Arizona study suggest that one method the brain uses to counter these diseases is the reassigning of tasks to different regions.
As Pisgah Laboratories, Inc. continues development of its lead abuse deterrent opioid product, it will soon begin scale-up of its patent-pending form of hydrocodone. Pisgah has developed a specialized salt form of hydrocodone which imparts abuse deterrent properties to a dosage product. Pisgah will manufacture its hydrocodone salt for clinical trials in their FDA / DEA registered facility.
In the US, child-resistant packaging for most medications has contributed to the prevention of thousands of pediatric deaths. Nevertheless, over 500,000 calls are made to poison control centers each year after accidental ingestion of medications by young children, and the number of emergency department visits for unsupervised medication ingestions is rising.
Oxford Gene Technology, provider of innovative genetics research and biomarker solutions to advance molecular medicine, has released the results from a recent survey of researchers using next generation sequencing.
› Verified 7 days ago
| Entity Name | Mayo Clinic Health System-southeast Minnesota Region |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1891701637 PECOS PAC ID: 4385556703 Enrollment ID: O20031104000408 |
News Archive
The brain continues to put up a fight even as neurodegenerative diseases like dementia damage certain areas and functions. In fact, recent findings in a Baycrest-University of Arizona study suggest that one method the brain uses to counter these diseases is the reassigning of tasks to different regions.
As Pisgah Laboratories, Inc. continues development of its lead abuse deterrent opioid product, it will soon begin scale-up of its patent-pending form of hydrocodone. Pisgah has developed a specialized salt form of hydrocodone which imparts abuse deterrent properties to a dosage product. Pisgah will manufacture its hydrocodone salt for clinical trials in their FDA / DEA registered facility.
In the US, child-resistant packaging for most medications has contributed to the prevention of thousands of pediatric deaths. Nevertheless, over 500,000 calls are made to poison control centers each year after accidental ingestion of medications by young children, and the number of emergency department visits for unsupervised medication ingestions is rising.
Oxford Gene Technology, provider of innovative genetics research and biomarker solutions to advance molecular medicine, has released the results from a recent survey of researchers using next generation sequencing.
› Verified 7 days ago
| Entity Name | Mayo Clinic Health System-southwest Minnesota Region |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1578545422 PECOS PAC ID: 4688585771 Enrollment ID: O20031110000134 |
News Archive
The brain continues to put up a fight even as neurodegenerative diseases like dementia damage certain areas and functions. In fact, recent findings in a Baycrest-University of Arizona study suggest that one method the brain uses to counter these diseases is the reassigning of tasks to different regions.
As Pisgah Laboratories, Inc. continues development of its lead abuse deterrent opioid product, it will soon begin scale-up of its patent-pending form of hydrocodone. Pisgah has developed a specialized salt form of hydrocodone which imparts abuse deterrent properties to a dosage product. Pisgah will manufacture its hydrocodone salt for clinical trials in their FDA / DEA registered facility.
In the US, child-resistant packaging for most medications has contributed to the prevention of thousands of pediatric deaths. Nevertheless, over 500,000 calls are made to poison control centers each year after accidental ingestion of medications by young children, and the number of emergency department visits for unsupervised medication ingestions is rising.
Oxford Gene Technology, provider of innovative genetics research and biomarker solutions to advance molecular medicine, has released the results from a recent survey of researchers using next generation sequencing.
› Verified 7 days ago
| Entity Name | Mayo Clinic Health System-fairmont |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1366410862 PECOS PAC ID: 4981694981 Enrollment ID: O20040719000142 |
News Archive
The brain continues to put up a fight even as neurodegenerative diseases like dementia damage certain areas and functions. In fact, recent findings in a Baycrest-University of Arizona study suggest that one method the brain uses to counter these diseases is the reassigning of tasks to different regions.
As Pisgah Laboratories, Inc. continues development of its lead abuse deterrent opioid product, it will soon begin scale-up of its patent-pending form of hydrocodone. Pisgah has developed a specialized salt form of hydrocodone which imparts abuse deterrent properties to a dosage product. Pisgah will manufacture its hydrocodone salt for clinical trials in their FDA / DEA registered facility.
In the US, child-resistant packaging for most medications has contributed to the prevention of thousands of pediatric deaths. Nevertheless, over 500,000 calls are made to poison control centers each year after accidental ingestion of medications by young children, and the number of emergency department visits for unsupervised medication ingestions is rising.
Oxford Gene Technology, provider of innovative genetics research and biomarker solutions to advance molecular medicine, has released the results from a recent survey of researchers using next generation sequencing.
› Verified 7 days ago
| Entity Name | Mayo Clinic Health System St James |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1023177730 PECOS PAC ID: 9537170352 Enrollment ID: O20060509000021 |
News Archive
The brain continues to put up a fight even as neurodegenerative diseases like dementia damage certain areas and functions. In fact, recent findings in a Baycrest-University of Arizona study suggest that one method the brain uses to counter these diseases is the reassigning of tasks to different regions.
As Pisgah Laboratories, Inc. continues development of its lead abuse deterrent opioid product, it will soon begin scale-up of its patent-pending form of hydrocodone. Pisgah has developed a specialized salt form of hydrocodone which imparts abuse deterrent properties to a dosage product. Pisgah will manufacture its hydrocodone salt for clinical trials in their FDA / DEA registered facility.
In the US, child-resistant packaging for most medications has contributed to the prevention of thousands of pediatric deaths. Nevertheless, over 500,000 calls are made to poison control centers each year after accidental ingestion of medications by young children, and the number of emergency department visits for unsupervised medication ingestions is rising.
Oxford Gene Technology, provider of innovative genetics research and biomarker solutions to advance molecular medicine, has released the results from a recent survey of researchers using next generation sequencing.
› Verified 7 days ago
| Entity Name | Mayo Clinic Health System-lake City |
|---|---|
| Entity Type | Part A Provider - Critical Access Hospital |
| Entity Identifiers | NPI Number: 1538113022 PECOS PAC ID: 1951213487 Enrollment ID: O20070711000490 |
News Archive
The brain continues to put up a fight even as neurodegenerative diseases like dementia damage certain areas and functions. In fact, recent findings in a Baycrest-University of Arizona study suggest that one method the brain uses to counter these diseases is the reassigning of tasks to different regions.
As Pisgah Laboratories, Inc. continues development of its lead abuse deterrent opioid product, it will soon begin scale-up of its patent-pending form of hydrocodone. Pisgah has developed a specialized salt form of hydrocodone which imparts abuse deterrent properties to a dosage product. Pisgah will manufacture its hydrocodone salt for clinical trials in their FDA / DEA registered facility.
In the US, child-resistant packaging for most medications has contributed to the prevention of thousands of pediatric deaths. Nevertheless, over 500,000 calls are made to poison control centers each year after accidental ingestion of medications by young children, and the number of emergency department visits for unsupervised medication ingestions is rising.
Oxford Gene Technology, provider of innovative genetics research and biomarker solutions to advance molecular medicine, has released the results from a recent survey of researchers using next generation sequencing.
› Verified 7 days ago
| Entity Name | Mayo Clinic Health System St James |
|---|---|
| Entity Type | Part A Provider - Critical Access Hospital |
| Entity Identifiers | NPI Number: 1639198732 PECOS PAC ID: 9537170352 Enrollment ID: O20080108000344 |
News Archive
The brain continues to put up a fight even as neurodegenerative diseases like dementia damage certain areas and functions. In fact, recent findings in a Baycrest-University of Arizona study suggest that one method the brain uses to counter these diseases is the reassigning of tasks to different regions.
As Pisgah Laboratories, Inc. continues development of its lead abuse deterrent opioid product, it will soon begin scale-up of its patent-pending form of hydrocodone. Pisgah has developed a specialized salt form of hydrocodone which imparts abuse deterrent properties to a dosage product. Pisgah will manufacture its hydrocodone salt for clinical trials in their FDA / DEA registered facility.
In the US, child-resistant packaging for most medications has contributed to the prevention of thousands of pediatric deaths. Nevertheless, over 500,000 calls are made to poison control centers each year after accidental ingestion of medications by young children, and the number of emergency department visits for unsupervised medication ingestions is rising.
Oxford Gene Technology, provider of innovative genetics research and biomarker solutions to advance molecular medicine, has released the results from a recent survey of researchers using next generation sequencing.
› Verified 7 days ago
| Entity Name | Mayo Clinic Health System-southwest Minnesota Region |
|---|---|
| Entity Type | Part A Provider - Critical Access Hospital |
| Entity Identifiers | NPI Number: 1740256668 PECOS PAC ID: 4688585771 Enrollment ID: O20171011003933 |
News Archive
The brain continues to put up a fight even as neurodegenerative diseases like dementia damage certain areas and functions. In fact, recent findings in a Baycrest-University of Arizona study suggest that one method the brain uses to counter these diseases is the reassigning of tasks to different regions.
As Pisgah Laboratories, Inc. continues development of its lead abuse deterrent opioid product, it will soon begin scale-up of its patent-pending form of hydrocodone. Pisgah has developed a specialized salt form of hydrocodone which imparts abuse deterrent properties to a dosage product. Pisgah will manufacture its hydrocodone salt for clinical trials in their FDA / DEA registered facility.
In the US, child-resistant packaging for most medications has contributed to the prevention of thousands of pediatric deaths. Nevertheless, over 500,000 calls are made to poison control centers each year after accidental ingestion of medications by young children, and the number of emergency department visits for unsupervised medication ingestions is rising.
Oxford Gene Technology, provider of innovative genetics research and biomarker solutions to advance molecular medicine, has released the results from a recent survey of researchers using next generation sequencing.
› Verified 7 days ago
| Entity Name | Mayo Clinic Health System-southwest Minnesota Region |
|---|---|
| Entity Type | Part A Provider - Critical Access Hospital |
| Entity Identifiers | NPI Number: 1124035282 PECOS PAC ID: 4688585771 Enrollment ID: O20171011003939 |
News Archive
The brain continues to put up a fight even as neurodegenerative diseases like dementia damage certain areas and functions. In fact, recent findings in a Baycrest-University of Arizona study suggest that one method the brain uses to counter these diseases is the reassigning of tasks to different regions.
As Pisgah Laboratories, Inc. continues development of its lead abuse deterrent opioid product, it will soon begin scale-up of its patent-pending form of hydrocodone. Pisgah has developed a specialized salt form of hydrocodone which imparts abuse deterrent properties to a dosage product. Pisgah will manufacture its hydrocodone salt for clinical trials in their FDA / DEA registered facility.
In the US, child-resistant packaging for most medications has contributed to the prevention of thousands of pediatric deaths. Nevertheless, over 500,000 calls are made to poison control centers each year after accidental ingestion of medications by young children, and the number of emergency department visits for unsupervised medication ingestions is rising.
Oxford Gene Technology, provider of innovative genetics research and biomarker solutions to advance molecular medicine, has released the results from a recent survey of researchers using next generation sequencing.
› Verified 7 days ago
| Entity Name | Mayo Clinic Health System-southeast Minnesota Region |
|---|---|
| Entity Type | Part A Provider - Critical Access Hospital |
| Entity Identifiers | NPI Number: 1063435410 PECOS PAC ID: 4385556703 Enrollment ID: O20171011003946 |
News Archive
The brain continues to put up a fight even as neurodegenerative diseases like dementia damage certain areas and functions. In fact, recent findings in a Baycrest-University of Arizona study suggest that one method the brain uses to counter these diseases is the reassigning of tasks to different regions.
As Pisgah Laboratories, Inc. continues development of its lead abuse deterrent opioid product, it will soon begin scale-up of its patent-pending form of hydrocodone. Pisgah has developed a specialized salt form of hydrocodone which imparts abuse deterrent properties to a dosage product. Pisgah will manufacture its hydrocodone salt for clinical trials in their FDA / DEA registered facility.
In the US, child-resistant packaging for most medications has contributed to the prevention of thousands of pediatric deaths. Nevertheless, over 500,000 calls are made to poison control centers each year after accidental ingestion of medications by young children, and the number of emergency department visits for unsupervised medication ingestions is rising.
Oxford Gene Technology, provider of innovative genetics research and biomarker solutions to advance molecular medicine, has released the results from a recent survey of researchers using next generation sequencing.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Michael Leigh Wells, MD 200 1st St Sw, Rochester, MN 55905-0001 Ph: (507) 284-2511 | Michael Leigh Wells, MD 200 1st St Sw, Rochester, MN 55905-0001 Ph: (507) 284-2511 |
News Archive
The brain continues to put up a fight even as neurodegenerative diseases like dementia damage certain areas and functions. In fact, recent findings in a Baycrest-University of Arizona study suggest that one method the brain uses to counter these diseases is the reassigning of tasks to different regions.
As Pisgah Laboratories, Inc. continues development of its lead abuse deterrent opioid product, it will soon begin scale-up of its patent-pending form of hydrocodone. Pisgah has developed a specialized salt form of hydrocodone which imparts abuse deterrent properties to a dosage product. Pisgah will manufacture its hydrocodone salt for clinical trials in their FDA / DEA registered facility.
In the US, child-resistant packaging for most medications has contributed to the prevention of thousands of pediatric deaths. Nevertheless, over 500,000 calls are made to poison control centers each year after accidental ingestion of medications by young children, and the number of emergency department visits for unsupervised medication ingestions is rising.
Oxford Gene Technology, provider of innovative genetics research and biomarker solutions to advance molecular medicine, has released the results from a recent survey of researchers using next generation sequencing.
› Verified 7 days ago
Michael Bold, M.D. Radiology Medicare: Accepting Medicare Assignments Practice Location: 200 1st St Sw, Rochester, MN 55905 Phone: 507-284-2511 | |
Allison E Garda, MD Radiology Medicare: Accepting Medicare Assignments Practice Location: 200 1st St Sw, Rochester, MN 55905 Phone: 507-284-2511 | |
Tanner Henrie, Radiology Medicare: Medicare Enrolled Practice Location: 200 1st St Sw, Rochester, MN 55905 Phone: 507-284-2511 | |
Philippe Couillard, Radiology Medicare: Not Enrolled in Medicare Practice Location: 200 1st St Sw, Rochester, MN 55905 Phone: 507-284-2511 | |
Scott Christopher Lester, MD Radiology Medicare: Accepting Medicare Assignments Practice Location: Mayo Clinic, 200 1st St Sw, Rochester, MN 55905 Phone: 507-284-2511 Fax: 507-284-0702 | |
Motassem Billah Nashawaty, MD Radiology Medicare: Medicare Enrolled Practice Location: 200 1st St Sw, Rochester, MN 55905 Phone: 507-284-2511 |